SG11201606758SA - Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders - Google Patents
Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disordersInfo
- Publication number
- SG11201606758SA SG11201606758SA SG11201606758SA SG11201606758SA SG11201606758SA SG 11201606758S A SG11201606758S A SG 11201606758SA SG 11201606758S A SG11201606758S A SG 11201606758SA SG 11201606758S A SG11201606758S A SG 11201606758SA SG 11201606758S A SG11201606758S A SG 11201606758SA
- Authority
- SG
- Singapore
- Prior art keywords
- dyslipidemia
- obesity
- diabetes
- treatment
- related disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14305494 | 2014-04-04 | ||
| PCT/EP2015/057414 WO2015150564A1 (en) | 2014-04-04 | 2015-04-02 | Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201606758SA true SG11201606758SA (en) | 2016-09-29 |
Family
ID=50513859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201606758SA SG11201606758SA (en) | 2014-04-04 | 2015-04-02 | Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9758520B2 (en) |
| EP (1) | EP3126336B1 (en) |
| JP (1) | JP2017509679A (en) |
| KR (1) | KR20160132885A (en) |
| CN (1) | CN106164073A (en) |
| AR (1) | AR099936A1 (en) |
| AU (1) | AU2015239021A1 (en) |
| CA (1) | CA2942753A1 (en) |
| CL (1) | CL2016002497A1 (en) |
| CR (1) | CR20160460A (en) |
| DO (1) | DOP2016000212A (en) |
| EA (1) | EA030410B1 (en) |
| EC (1) | ECSP16078779A (en) |
| IL (1) | IL248129A0 (en) |
| MA (1) | MA39346B1 (en) |
| MX (1) | MX2016013033A (en) |
| PE (1) | PE20161378A1 (en) |
| PH (1) | PH12016501619A1 (en) |
| SG (1) | SG11201606758SA (en) |
| TW (1) | TW201625605A (en) |
| WO (1) | WO2015150564A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR099936A1 (en) | 2014-04-04 | 2016-08-31 | Sanofi Sa | CONDENSED HETEROCICLES REPLACED AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DISLIPIDEMIA AND RELATED DISORDERS |
| DK3126354T3 (en) | 2014-04-04 | 2020-03-09 | H Lundbeck As | HALOGENATED QUINAZOLINE-THF AMINES AS PDE1 INHIBITORS |
| AR110988A1 (en) | 2017-02-21 | 2019-05-22 | Sanofi Sa | AZETIDINE COMPOUNDS AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS |
| WO2019043635A1 (en) | 2017-09-01 | 2019-03-07 | Richter Gedeon Nyrt. | D-amino acid oxidase activity inhibiting compounds |
| CN110548026B (en) * | 2018-05-31 | 2022-01-14 | 华领医药技术（上海）有限公司 | Pharmaceutical composition containing glucokinase activator and K-ATP channel blocker, and preparation method and application thereof |
| KR102131359B1 (en) * | 2018-09-07 | 2020-07-07 | 오토텔릭바이오 주식회사 | A pharmaceutical composition with an improved stability |
| CN114450011A (en) * | 2019-05-31 | 2022-05-06 | 阿沃林特有限公司 | Compositions and methods for treating metabolic disorders |
| CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
| CN116390925A (en) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | AMPK activator |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0410561A (en) * | 2003-06-18 | 2006-06-20 | Pfizer Prod Inc | piperazinyletheroaryl-n-arill and piperazinylaryloxy lactams |
| CN101426783B (en) * | 2006-04-21 | 2013-10-30 | 伊莱利利公司 | Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
| MX2012013465A (en) * | 2010-05-17 | 2013-12-02 | Array Biopharma Inc | Piperidinyl-substituted lactams as gpr119 modulators. |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| JP2013537234A (en) | 2010-09-17 | 2013-09-30 | アレイ バイオファーマ、インコーポレイテッド | Piperidinyl-substituted lactams as GPR119 modulators |
| AU2012336157A1 (en) | 2011-11-11 | 2014-05-29 | Glaxosmithkline Llc | Treatment of blood lipid abnormalities and other conditions |
| AR099936A1 (en) | 2014-04-04 | 2016-08-31 | Sanofi Sa | CONDENSED HETEROCICLES REPLACED AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DISLIPIDEMIA AND RELATED DISORDERS |
-
2015
- 2015-04-01 AR ARP150100989A patent/AR099936A1/en unknown
- 2015-04-01 TW TW104110619A patent/TW201625605A/en unknown
- 2015-04-02 CN CN201580017438.3A patent/CN106164073A/en active Pending
- 2015-04-02 KR KR1020167026911A patent/KR20160132885A/en unknown
- 2015-04-02 WO PCT/EP2015/057414 patent/WO2015150564A1/en active Application Filing
- 2015-04-02 JP JP2016560725A patent/JP2017509679A/en not_active Abandoned
- 2015-04-02 PE PE2016001909A patent/PE20161378A1/en not_active Application Discontinuation
- 2015-04-02 CR CR20160460A patent/CR20160460A/en unknown
- 2015-04-02 EP EP15713528.6A patent/EP3126336B1/en active Active
- 2015-04-02 MA MA39346A patent/MA39346B1/en unknown
- 2015-04-02 EA EA201692008A patent/EA030410B1/en not_active IP Right Cessation
- 2015-04-02 AU AU2015239021A patent/AU2015239021A1/en not_active Abandoned
- 2015-04-02 CA CA2942753A patent/CA2942753A1/en not_active Abandoned
- 2015-04-02 MX MX2016013033A patent/MX2016013033A/en unknown
- 2015-04-02 SG SG11201606758SA patent/SG11201606758SA/en unknown
-
2016
- 2016-08-15 DO DO2016000212A patent/DOP2016000212A/en unknown
- 2016-08-15 PH PH12016501619A patent/PH12016501619A1/en unknown
- 2016-09-29 IL IL248129A patent/IL248129A0/en unknown
- 2016-09-30 CL CL2016002497A patent/CL2016002497A1/en unknown
- 2016-10-03 US US15/284,213 patent/US9758520B2/en not_active Expired - Fee Related
- 2016-10-04 EC ECIEPI201678779A patent/ECSP16078779A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9758520B2 (en) | 2017-09-12 |
| PH12016501619A1 (en) | 2017-02-06 |
| JP2017509679A (en) | 2017-04-06 |
| TW201625605A (en) | 2016-07-16 |
| AR099936A1 (en) | 2016-08-31 |
| MA39346A1 (en) | 2017-09-29 |
| IL248129A0 (en) | 2016-11-30 |
| CA2942753A1 (en) | 2015-10-08 |
| WO2015150564A1 (en) | 2015-10-08 |
| EP3126336A1 (en) | 2017-02-08 |
| CR20160460A (en) | 2017-02-21 |
| CL2016002497A1 (en) | 2017-03-31 |
| CN106164073A (en) | 2016-11-23 |
| EP3126336B1 (en) | 2018-12-05 |
| EA201692008A1 (en) | 2017-02-28 |
| MX2016013033A (en) | 2017-01-09 |
| DOP2016000212A (en) | 2016-11-15 |
| US20170022198A1 (en) | 2017-01-26 |
| AU2015239021A1 (en) | 2016-10-13 |
| ECSP16078779A (en) | 2017-02-24 |
| PE20161378A1 (en) | 2016-12-26 |
| MA39346B1 (en) | 2019-03-29 |
| EA030410B1 (en) | 2018-07-31 |
| KR20160132885A (en) | 2016-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285114B1 (en) | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | |
| IL248130A0 (en) | Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | |
| IL258402B1 (en) | Electroporation for obesity or diabetes treatment | |
| HK1231417A1 (en) | Compounds for treating ophthalmic diseases and disorders | |
| IL247841A0 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| IL248129A0 (en) | Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | |
| IL248118A0 (en) | Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | |
| SG11201608729RA (en) | Membrane-adherent self-assembled systems for treatment of ocular disorders | |
| SG11201705194XA (en) | Pharmaceutical composition for treating diabetes | |
| PL3145511T3 (en) | Composition for treating the eye | |
| PT3160464T (en) | 6-hydroxybuspirone for use in the treatment of movement disorders | |
| DK3209295T3 (en) | PROCEDURES FOR THE TREATMENT OF EYE DISORDERS | |
| EP3206675A4 (en) | METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs | |
| HK1251449A1 (en) | Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes | |
| MA54630A (en) | N,N-BIS-2-MERCAPTOETHYL ISOPHTALAMIDE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| HK1257593A1 (en) | New drug for treating diabetes and use thereof | |
| GB201412935D0 (en) | Materials for use with hyperthermia treatment | |
| IL266311A (en) | Therapeutic drug or prophylactic drug for diabetic nephropathy | |
| AU2014901052A0 (en) | Device for the treatment of snoring. | |
| SG10201400823PA (en) | Therapeutic methods and compositions for treating diabetes | |
| GB201413532D0 (en) | Combination therapy for treating hearing disorders |